Top

Published in:

01-12-2012 | Research Article

ING4 is negatively correlated with microvessel density in colon cancer

Authors: Chun Lou, Shixiong Jiang, Xinggang Guo, Xin-shu Dong

Published in: Tumor Biology | Issue 6/2012

Abstract

ING4 is a novel tumor suppressor which is downregulated in a number of cancers. In this study, we investigated the role of ING4 in tumor angiogenesis in colorectal carcinoma (CRC) patients. Semi-quantitative RT-PCR, western blots, and immunohistochemistry were used to determine ING4 mRNA and protein expression in CRC and normal tissue from 60 CRC specimens and 30 colonic adenoma specimens. The correlation between ING4 expression and clinical stage, histological grade as well as lymph node metastasis was evaluated. Immunohistochemistry was performed to explore the correlation between ING4 expression and microvessel density (MVD) in CRC. CRC tissue had significantly lower levels of ING4 mRNA and protein compared to colonic adenoma and normal intestinal tissue. Immunostaining showed ING4 expression in 38 (63.3 %), 30 (100 %), and 60 (100 %) cases of normal colonic mucosa, adenoma, and normal intestinal mucosal tissue, respectively. Lower ING4 levels correlated with higher clinical stage and histological grade. ING4 mRNA and protein levels were significantly lower in CRC patients with lymph node metastasis compared to patients without lymph node metastasis (0.41 ± 0.30 vs. 0.91 ± 0.29 and 0.60 ± 0.21 vs. 0.87 ± 0.27, respectively; p < 0.001). Importantly, ING4 mRNA and protein levels were negatively correlated with MVD in CRC patients (p < 0.001). Our data suggest that ING4 levels are a potential biomarker of CRC progression and that ING4 may inhibit tumor growth by modulating angiogenesis in CRC.

Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet. 2010;375:1030–47.PubMedCrossRef

Levin B, Lieberman DA, McFarland B, et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer J Clin. 2008;58:130–60.PubMedCrossRef

Sung JJ, Lau JY, Goh KL, et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol. 2005;6:871–6.PubMedCrossRef

Hawk ET, Levin B. Colorectal cancer prevention. J Clin Oncol. 2005;23:378–91.PubMedCrossRef

You Q, Wang XS, Fu SB, et al. Downregulated expression of inhibitor of growth 4 (ING4) in advanced colorectal cancers: a non-randomized experimental study. Pathol Oncol Res. 2011;17:473–7.PubMedCrossRef

Unoki M, Kumamoto K, Takenoshita S, et al. Reviewing the current classification of inhibitor of growth family proteins. Cancer Sci. 2009;100:1173–9.PubMedCrossRef

Xie Y, Lv H, Sheng W, et al. Synergistic tumor suppression by adenovirus-mediated inhibitor of growth 4 and interleukin-24 gene cotransfer in hepatocarcinoma cells. Cancer Biother Radiopharm. 2011;26:681–95.PubMedCrossRef

Kim S. HuntING4 new tumor suppressors. Cell Cycle. 2005;4:516–7.PubMedCrossRef

Kim S, Chin K, Gray JW, et al. A screen for genes that suppress loss of contact inhibition: identification of ING4 as a candidate tumor suppressor gene in human cancer. Proc Natl Acad Sci U S A. 2004;101:16251–6.PubMedCrossRef

10.

Shiseki M, Nagashima M, Pedeux RM, et al. p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res. 2003;63:2373–8.PubMed

11.

Zhang X, Xu LS, Wang ZQ, et al. ING4 induces G2/M cell cycle arrest and enhances the chemosensitivity to DNA-damage agents in HepG2 cells. FEBS Lett. 2004;570:7–12.PubMedCrossRef

12.

Shen JC, Unoki M, Ythier D, et al. Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res. 2007;67:2552–8.PubMedCrossRef

13.

Colla S, Tagliaferri S, Morandi F, et al. The new tumor-suppressor gene inhibitor of growth family member 4 (ING4) regulates the production of proangiogenic molecules by myeloma cells and suppresses hypoxia-inducible factor-1 alpha (HIF-1alpha) activity: involvement in myeloma-induced angiogenesis. Blood. 2007;110:4464–75.PubMedCrossRef

14.

Ozer A, Bruick RK. Regulation of HIF by prolyl hydroxylases: recruitment of the candidate tumor suppressor protein ING4. Cell Cycle. 2005;4:1153–6.PubMedCrossRef

15.

Ozer A, Wu LC, Bruick RK. The candidate tumor suppressor ING4 represses activation of the hypoxia inducible factor (HIF). Proc Natl Acad Sci U S A. 2005;102:7481–6.PubMedCrossRef

16.

Li J, Martinka M, Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis. 2008;29:1373–9.PubMedCrossRef

17.

Bhattacharya A, Turowski SG, San Martin ID, et al. Magnetic resonance and fluorescence-protein imaging of the anti-angiogenic and anti-tumor efficacy of selenium in an orthotopic model of human colon cancer. Anticancer Res. 2011;31:387–93.PubMed

18.

Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes Memorial Award Lecture. Cancer Res. 1986;46:467–73.PubMed

19.

Rubatt JM, Darcy KM, Hutson A, et al. Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a gynecologic oncology group study. Gynecol Oncol. 2009;112:469–74.PubMedCrossRef

20.

Liu H, Wan D, Pan Z, et al. Expression and biological significance of leptin, leptin receptor, VEGF, and CD34 in colorectal carcinoma. Cell Biochem Biophys. 2011;60:241–4.PubMedCrossRef

21.

Rajaganeshan R, Prasad R, Guillou PJ, et al. The influence of invasive growth pattern and microvessel density on prognosis in colorectal cancer and colorectal liver metastases. Br J Cancer. 2007;96:1112–7.PubMedCrossRef

22.

Tanigawa N, Amaya H, Matsumura M, et al. Tumor angiogenesis and mode of metastasis in patients with colorectal cancer. Cancer Res. 1997;57:1043–6.PubMed

23.

Xie YF, Sheng W, Xiang J, et al. Adenovirus-mediated ING4 expression suppresses pancreatic carcinoma cell growth via induction of cell-cycle alteration, apoptosis, and inhibition of tumor angiogenesis. Cancer Biother Radiopharm. 2009;24:261–9.PubMedCrossRef

24.

Fang F, Luo LB, Tao YM, et al. Decreased expression of inhibitor of growth 4 correlated with poor prognosis of hepatocellular carcinoma. Cancer Epidemiol Biomark Prev. 2009;18:409–16.CrossRef

25.

Weidner N. Tumor angiogenesis: review of current applications in tumor prognostication. Semin Diagn Pathol. 1993;10:302–13.PubMed

26.

Wang QS, Li M, Zhang LY, et al. Down-regulation of ING4 is associated with initiation and progression of lung cancer. Histopathology. 2010;57:271–81.PubMedCrossRef

27.

Gunduz M, Nagatsuka H, Demircan K, et al. Frequent deletion and down-regulation of ING4, a candidate tumor suppressor gene at 12p13, in head and neck squamous cell carcinomas. Gene. 2005;356:109–17.PubMedCrossRef

28.

Li XH, Kikuchi K, Zheng Y, et al. Downregulation and translocation of nuclear ING4 is correlated with tumorigenesis and progression of head and neck squamous cell carcinoma. Oral Oncol. 2011;47:217–23.PubMedCrossRef

29.

Klironomos G, Bravou V, Papachristou DJ, et al. Loss of inhibitor of growth (ING-4) is implicated in the pathogenesis and progression of human astrocytomas. Brain Pathol. 2010;20:490–7.PubMedCrossRef

30.

Raho G, Miranda C, Tamborini E, et al. Detection of novel mRNA splice variants of human ING4 tumor suppressor gene. Oncogene. 2007;26:5247–57.PubMedCrossRef

31.

Goodheart MJ, Ritchie JM, Rose SL, et al. The relationship of molecular markers of p53 function and angiogenesis to prognosis of stage I epithelial ovarian cancer. Clin Cancer Res. 2005;11:3733–42.PubMedCrossRef

32.

Doekhie FS, Morreau H, de Bock GH, et al. Sialyl Lewis X expression and lymphatic microvessel density in primary tumors of node-negative colorectal cancer patients predict disease recurrence. Cancer Microenviron. 2008;1:141–51.PubMedCrossRef

33.

Labiche A, Elie N, Herlin P, et al. Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma. Histol Histopathol. 2009;24:425–35.PubMed

34.

Rasheed S, Harris AL, Tekkis PP, et al. Hypoxia-inducible factor-1alpha and -2alpha are expressed in most rectal cancers but only hypoxia-inducible factor-1alpha is associated with prognosis. Br J Cancer. 2009;100:1666–73.PubMedCrossRef

35.

Barresi V, Di Gregorio C, Regiani-Bonetti L, et al. Stage I colorectal carcinoma: VEGF immunohistochemical expression, microvessel density, and their correlation with clinical outcome. Virchows Arch. 2010;457:11–9.PubMedCrossRef

36.

Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature. 2004;428:328–32.PubMedCrossRef

37.

Brat DJ, Bellail AC, Van Meir EG. The role of interleukin-8 and its receptors in gliomagenesis and tumoral angiogenesis. Neuro Oncol. 2005;7:122–33.PubMedCrossRef

38.

Desbaillets I, Diserens AC, de Tribolet N, et al. Regulation of interleukin-8 expression by reduced oxygen pressure in human glioblastoma. Oncogene. 1999;18:1447–56.PubMedCrossRef

39.

Li J, Li G. Cell cycle regulator ING4 is a suppressor of melanoma angiogenesis that is regulated by the metastasis suppressor BRMS1. Cancer Res. 2010;70:10445–53.PubMedCrossRef

40.

Li M, Jun Y, Sun W-J. Reduced expression and novel splice variants ofING4 in human gastric adenocarcinoma. J Pathol. 2009;219:87–95.PubMedCrossRef

41.

Li X, Cai L, Liang M, et al. ING4 induces cell growth inhibition in human lung adenocarcinoma A549 cells by means of Wnt-1/beta-catenin signaling pathway. Anat Rec (Hoboken). 2008;291:593–600.CrossRef

Title: ING4 is negatively correlated with microvessel density in colon cancer
Authors: Chun Lou
Shixiong Jiang
Xinggang Guo
Xin-shu Dong
Publication date: 01-12-2012
Publisher: Springer Netherlands
Published in: Tumor Biology / Issue 6/2012
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-012-0498-9

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Association of autotaxin and lysophosphatidic acid receptor 3 with aggressiveness of human breast carcinoma

CYP1A1 Ile462Val polymorphism and cervical cancer: evidence from a meta-analysis

Negative regulation of cell motile and invasive activities by lysophosphatidic acid receptor-3 in colon cancer HCT116 cells

SCC-S2 is overexpressed in colon cancers and regulates cell proliferation

Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients

Quantitative assessment of the association between MTHFR C677T polymorphism and colorectal cancer risk in East Asians

Keynote webinar | Spotlight on antibody–drug conjugates in cancer